Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk

Journal of Clinical Lipidology

Volumn 10, Issue 6, 2016, Pages 1389-1396

  Yeang, Calvin ^a   Clopton, Paul C ^b   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

HDL Cholesterol; Lipoprotein(a); Lipoprotein(a) cholesterol; Niacin; Oxidized phospholipids; VAP

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; NICOTINIC ACID; PHOSPHOLIPID; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ADOLESCENT; BLOOD; CHEMISTRY; COMBINATION DRUG THERAPY; FEMALE; HYPERLIPOPROTEINEMIAS; MALE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEIN(A); MALE; MIDDLE AGED; NIACIN; PHOSPHOLIPIDS; SIMVASTATIN; TRIGLYCERIDES; YOUNG ADULT;

EID: 85002062880     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2016.09.012     Document Type: Article

References (36)

1. 1 Bergmark, C., Dewan, A., Orsoni, A., et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 49 (2008), 2230–2239.
2. 2 Leibundgut, G., Scipione, C., Yin, H., et al. Determinants of binding of oxidized phospholipids on apolipoprotein(a) and lipoprotein(a). J Lipid Res 54 (2013), 2815–2830.
3. 3 Erqou, S., Kaptoge, S., Perry, P.L., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302 (2009), 412–423.
4. 4 Marcovina, S.M., Albers, J.J., Lipoprotein (a) measurements for clinical application. J Lipid Res 57 (2016), 526–537.
5. 5 Kamstrup, P.R., Tybjaerg-Hansen, A., Steffensen, R., Nordestgaard, B.G., Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301 (2009), 2331–2339.
6. 6 Bertoia, M.L., Pai, J.K., Lee, J.H., et al. Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol 61 (2013), 2169–2179.
7. 7 Yeang, C., Wilkinson, M.J., Tsimikas, S., Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. Curr Opin Cardiol 31 (2016), 440–450.
8. 8 Capoulade, R., Chan, K.L., Yeang, C., et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol 66 (2015), 1236–1246.
9. 9 Seman, L.J., Breckenridge, W.C., Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a). Biochem Cell Biol 64 (1986), 999–1009.
10. 10 Marcovina, S.M., Albers, J.J., Scanu, A.M., et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 46 (2000), 1956–1967.
11. 11 Fless, G.M., ZumMallen, M.E., Scanu, A.M., Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a). J Biol Chem 261 (1986), 8712–8718.
12. 12 Elshazly, M.B., Martin, S.S., Blaha, M.J., et al. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids). J Am Coll Cardiol 62 (2013), 1960–1965.
13. 13 Yeang, C., Witztum, J.L., Tsimikas, S., ‘LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol 26 (2015), 169–178.
14. 14 Willeit, P., Kiechl, S., Kronenberg, F., et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 64 (2014), 851–860.
15. 15 Kulkarni, K.R., Garber, D.W., Marcovina, S.M., Segrest, J.P., Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 35 (1994), 159–168.
16. 16 Guyton, J.R., Brown, B.G., Fazio, S., Polis, A., Tomassini, J.E., Tershakovec, A.M., Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 51 (2008), 1564–1572.
17. 17 Yeang, C., Hung, M.Y., Byun, Y.S., et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). J Clin Lipidol 10 (2016), 594–603.
18. 18 Tsimikas, S., Mallat, Z., Talmud, P.J., et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 56 (2010), 946–955.
19. 19 Verbeek, R., Boekholdt, S.M., Stoekenbroek, R.M., et al. Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. J Lipid Res 57 (2016), 697–705.
20. 20 Taleb, A., Witztum, J.L., Tsimikas, S., Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med 5 (2011), 673–694.
21. 21 Byun, Y.S., Lee, J.H., Arsenault, B.J., et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol 65 (2015), 1286–1295.
22. 22 Havel, R.J., Eder, H.A., Bragdon, J.H., Distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 (1955), 1345–1353.
23. 23 Arai, K., Orsoni, A., Mallat, Z., et al. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res 53 (2012), 1670–1678.
24. 24 Albers, J.J., Hazzard, W.R., Immunochemical quantification of human plasma Lp(a) lipoprotein. Lipids 9 (1974), 15–26.
25. 25 Dati, F., Tate, J.R., Marcovina, S.M., et al. First WHO/IFCC international reference reagent for lipoprotein(a) for immunoassay–Lp(a) SRM 2B. Clin Chem Lab Med 42 (2004), 670–676.
26. 26 Albers, J.J., Slee, A., O'Brien, K.D., et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 62 (2013), 1575–1579.
27. 27 Sharma, S., Merchant, J., Fleming, S.E., Lp(a)-cholesterol is associated with HDL-cholesterol in overweight and obese African American children and is not an independent risk factor for CVD. Cardiovasc Diabetol, 11, 2012, 10.
28. 28 Konerman, M., Kulkarni, K., Toth, P.P., Jones, S.R., Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups. J Clin Lipidol 6 (2012), 368–373.
29. 29 Lu, W., Cheng, Y.C., Chen, K., et al. Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels. Hum Mol Genet 24 (2015), 2390–2400.
30. 30 Sharma, M., Von Zychlinski-Kleffmann, A., Porteous, C.M., Jones, G.T., Williams, M.J., McCormick, S.P., Lipoprotein (a) upregulates ABCA1 in liver cells via scavenger receptor-B1 through its oxidized phospholipids. J Lipid Res 56 (2015), 1318–1328.
31. 31 Tsimikas, S., Clopton, P., Brilakis, E.S., et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 119 (2009), 1711–1719.
32. 32 Fraley, A.E., Schwartz, G.G., Olsson, A.G., et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol 53 (2009), 2186–2196.
33. 33 Lamon-Fava, S., Marcovina, S.M., Albers, J.J., et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res 52 (2011), 1181–1187.
34. 34 Tsimikas, S., Viney, N.J., Hughes, S.G., et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386 (2015), 1472–1483.
35. 35 Raal, F.J., Giugliano, R.P., Sabatine, M.S., et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 63 (2014), 1278–1288.
36. 36 Gaudet, D., Kereiakes, D.J., McKenney, J.M., et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 114 (2014), 711–715.